Find an Eye MD near you!

To compare the 6-month efficacy and safety profile of an individualized stabilization criteria–driven pro re nata (PRN) regimen of ranibizumab 0.5 mg with or without laser versus laser alone in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO).


Read full article on AAO Journal



Twitter

Diagnose This: Minimizing ocular movement during phacoemulsification

◦Attention colleagues! Please reach out to your member of Congress regarding the rising drug prices and lack of tra… https://t.co/XKu7NezQAj

Looks like a great weekend for the WVAEPS 2018 Scientific Conference at the Greenbrier!!! Hope you made your regis… https://t.co/CNa5LLXj1t

Suffering eye strain at work? Follow these tips from the American Academy of Ophthalmology to get some relief. https://t.co/tfR8etzzG9